Mocarski E S, Kemble G W, Lyle J M, Greaves R F
Department of Microbiology and Immunology, Stanford University School of Medicine, CA 94305-5402, USA.
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11321-6. doi: 10.1073/pnas.93.21.11321.
Human cytomegalovirus (CMV) replication begins with the expression of two regulatory proteins, IE1(491aa) and IE2(579aa), produced from differentially spliced transcripts under control of the ie1/ie2 promoter-enhancer. A deletion mutation removing all 406 IE1(491aa)-specific amino acids was engineered into the viral genome and this mutant (RC303 delta Acc) was propagated on an IE1(491aa)-expressing human fibroblast cell line (ihfie1.3). RC303 delta Acc failed to replicate on normal human fibroblasts at low multiplicities of infection (mois). At mois > 3 plaque-forming units per cell, virus replication and production of progeny were comparable to wild type. However, at mois between 0.01 and 1, mutant virus replicated slowly on normal fibroblasts, a pattern that suggested initiation of productive infection required multiple hits. Replication of RC303 delta Acc correlated with the ability to express IE2(579aa), consistent with a role for IE1(491aa) in positive autoregulation of the ie1/ie2 promoter-enhancer and with data suggesting that virion transactivators compensate for the lack of IE1(491aa) under high moi conditions. ie1-deficient CMV should be completely avirulent, suggesting its utility as a gene therapy vector for hematopoietic progenitors that are normal sites of CMV latency.
人类巨细胞病毒(CMV)的复制始于两种调节蛋白IE1(491个氨基酸)和IE2(579个氨基酸)的表达,这两种蛋白由在ie1/ie2启动子 - 增强子控制下的差异剪接转录本产生。一种缺失突变体被构建到病毒基因组中,该突变体去除了所有406个IE1(491个氨基酸)特异性氨基酸,这种突变体(RC303 delta Acc)在表达IE1(491个氨基酸)的人成纤维细胞系(ihfie1.3)上增殖。在低感染复数(MOI)下,RC303 delta Acc在正常人成纤维细胞上无法复制。在每个细胞MOI>3个噬斑形成单位时,病毒复制和子代产生与野生型相当。然而,在MOI为0.01至1之间时,突变病毒在正常人成纤维细胞上复制缓慢,这种模式表明生产性感染的起始需要多次感染。RC303 delta Acc的复制与表达IE2(579个氨基酸)的能力相关,这与IE1(491个氨基酸)在ie1/ie2启动子 - 增强子的正向自调节中的作用一致,并且与数据表明在高MOI条件下病毒体反式激活因子可补偿IE1(491个氨基酸)的缺乏一致。缺乏ie1的CMV应该是完全无毒的,这表明它作为一种基因治疗载体对于作为CMV潜伏正常位点的造血祖细胞的实用性。